Drug intelligence / Profile preview

TLX-012

Development stage: Preclinical
Lead developer: Easywell Biomedicals
Modality: Small Molecules

Overview

TLX-012 is a small molecule drug candidate being developed by Easywell Biomedicals for the treatment of epilepsy. It is categorized as a new chemical entity (NCE) within the company's central nervous system (CNS) therapeutic pipeline. Currently in the preclinical stage of development, TLX-012 is designed to address the needs of patients with seizure disorders, although its specific molecular target and mechanism of action have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on TLX-012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLX-012.

Explore the full profile